Since the discovery of reprogramming factors in 2006 and the boom of CRISPR gene editing strategies, induced pluripotent stem cells (iPSC) have emerged as new cellular models. The development of 3D cell culture technologies has also contributed to the generation of induced Pluripotent Stem Cell (iPSC) derived cells, with unique applications from patient-specific drug responses testing, to regenerative medicine. I would like to introduce in this post a selection of reagents in this domain, a combination of both routine and innovative quality reagents, that I consider as bringing something extra to your stem cell research projects.
Today, I’d like to invite you to take a look at a highly efficient and useful kit, which brings together all the required components you need in a complete system for culturing and transfecting human pluripotent stem cells for gene editing.
The PluriQ™ G9™ Gene Editing System includes the G9™ Maintenance Medium and G9™ VTN Recombinant (vitronectin) plate coating for culturing human induced pluripotent (iPS) or embryonic stem (hES) cells in a manner that maximizes transfection by the included EditPro™ Stem Transfection Reagent to transfect genome editing constructs. [Read more…]
I have to admit that I never received the Fields Medal in Mathematics. Therefore, I won’t be able to develop this equation and prove that I’m right. However, what I can prove, is that in cell culture, 2 = 5. How is this possible?
Human induced pluripotent stem (iPS) cells and cells differentiated from iPS cells have widely been used for in vivo models human disease progression. Jason Meyer, of Indiana University Purdue University Indianapolis, uses iPS cell-derived models to study retinogenesis and retinal disease. Two recent papers from his lab highlight the benefits of using Stemgent’s RNA reprogramming technology to enable robust differentiation of iPS cells to the retinal lineage (1, 2). RNA reprogramming technology was chosen in order for these studies to ensure that no vestiges of the reprogramming vectors were retained by the cells or integrated into the genome.
The introduction of transgenes into stem cells has shown to be a valuable experimental technique for studying stem cell biology. Transfecting stem cells without inhibiting cell viability and cell growth has shown to be difficult. DNA-In® Stem Transfection Reagent offers a simple, robust and reproducible method for delivering DNA into a wide range of stem cells, including neural stem cells. Formulated and optimized specifically for embryonic and adult stem cells, DNA-In® Stem is a new-generation transfection reagent that enables high efficiency transfection while maintaining maximum cell viability and cell growth.
In this post, I invite you to discover the benefits of using DNA-In® Stem Transfection Reagent vs. other reagents. A lot of pictures and graphs rather than long descriptions! Last but not least, DNA-In® Stem Transfection Reagent is less expensive compared to Lipofectamine reagents… [Read more…]
Lipotransfers are ideal for restorative surgery, but retention is a problem. In a recent study, PRP grade concentrated platelets were used for a study examining how platelet-rich plasma helps to enhance fat graft survival.
In this age of crash diets and liposuction, it might sound surprising that some people receive fat transplants. But seriously, fat grafting is widely used and valued as a feasible method for addressing moderate defects caused by injuries, surgical removal of tumours, and congenital deficiencies. Fat grafting is safe and has the look and feel of normal soft tissue. However, long-term volume retention is suboptimal (30-70%), often requiring multiple surgeries. [Read more…]
Stem Cells: a great tool for biomedical research! From the embryo at a very early stage of development, stem cells have two important capabilities: to multiply to infinity by simple division and to give rise to all kind of cells of the organism. These properties offer many opportunities, not only for the regenerative medicine but also for the study of genetic diseases and development of new treatments.
One of the first thing to do when you’re working on this kind of cells is to check if they are really stem cells, i.e their stemness. It can be highlighted by different markers by IF, WB, etc…
Today, I invite you to look at a popular antibody allowing you to monitor the level of differentiation of your cellular model as well as an innovation related to antibody array and stem cell research.
Induced-pluripotent stem cells (iPSC) are produced from a variety of source tissues including fibroblasts, epithelial progenitor cells, peripheral blood mononucleocytes (PBMC), and others. For Human iPSC, the pluripotency state is sometimes referred to as the “primed” state. Among iPSC lines, heterogeneity has been shown to exist in proliferation and the capacity to differentiate. This can cause issues in data interpretation or even limit the utility of Human iPSC in some disease cell models for basic research or drug discovery.
Recent publications have shown that Human iPSC, when cultured under special conditions, can be transitioned to what may be a more primitive form perhaps similar to cells in the pre-implantation state of a developing embryo. This state is referred to as the “naïve” state. In mouse and rabbit iPSC systems, naïve state cells have been shown to increase the efficiency and reproducibility (less bias) of terminal differentiation, including giving rise to some terminally differentiated cell types that display greater maturity. Thanks to this evidence (in other species), the accelerated growth characteristics of naïve cells, and other attributes linked to pluripotency, there is worldwide a rapidly growing interest in the Human stem cell research community. [Read more…]
CRISPR-Cas9 is a popular method that brings researchers endless experimental strategies to create their own research-based cellular models. In this post we’ll review a new transfection reagent especially engineered to maximize Cas9 vectors deliveries inside cells with low cellular toxicity.
Newly added to the Stemolecule portfolio are three small molecules which support a new approach for the derivation and maintenance of naïve human pluripotent stem cells. These three newly identified small molecules, WH-4-023, SB590885 and IM-12, are all kinase inhibitors.